Following a string of FDA resignations, Patrizia Cavazzoni has announced that her last day will be 18 January.
Climb Bio has entered an exclusive licence agreement with Beijing Mabworks Biotech for developing and commercialising CLYM116.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback